UY32111A - Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad - Google Patents
Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedadInfo
- Publication number
- UY32111A UY32111A UY0001032111A UY32111A UY32111A UY 32111 A UY32111 A UY 32111A UY 0001032111 A UY0001032111 A UY 0001032111A UY 32111 A UY32111 A UY 32111A UY 32111 A UY32111 A UY 32111A
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitors
- treatment
- heterociclic
- disease
- histamine receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención está relacionada compuestos y métodos que pueden ser útiles como inhibidores de H1R y/o H4R para el tratamiento o la prevención de enfermedades inflamatorias, autoinmunes, alérgicas y oculares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9582608P | 2008-09-10 | 2008-09-10 | |
US23174909P | 2009-08-06 | 2009-08-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32111A true UY32111A (es) | 2010-04-30 |
Family
ID=42005738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032111A UY32111A (es) | 2008-09-10 | 2009-09-10 | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad |
Country Status (14)
Country | Link |
---|---|
US (2) | US20100120741A1 (es) |
EP (1) | EP2324029A4 (es) |
JP (1) | JP2012502067A (es) |
KR (1) | KR20110095857A (es) |
CN (1) | CN102388044A (es) |
AR (1) | AR073574A1 (es) |
AU (1) | AU2009291719A1 (es) |
CA (1) | CA2735369A1 (es) |
CL (1) | CL2011000431A1 (es) |
MX (1) | MX2011002264A (es) |
RU (1) | RU2011113419A (es) |
TW (1) | TW201024297A (es) |
UY (1) | UY32111A (es) |
WO (1) | WO2010030785A2 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102004031656A1 (de) * | 2004-06-30 | 2006-01-19 | Merck Patent Gmbh | Tetrahydrochinoline |
PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
TWI547522B (zh) | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | 環氧乙烷環氧丁烷嵌段共聚物組成物 |
US20110065698A1 (en) * | 2009-08-26 | 2011-03-17 | Cylene Pharmaceuticals, Inc. | Novel protein kinase modulators |
JP2013053070A (ja) * | 2009-11-06 | 2013-03-21 | Takeda Chem Ind Ltd | ジヒドロピロロキノリン誘導体 |
TW201200518A (en) * | 2010-03-10 | 2012-01-01 | Kalypsys Inc | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
DE102010025786A1 (de) * | 2010-07-01 | 2012-01-05 | Merck Patent Gmbh | Pyrazolochinoline |
TW201206936A (en) | 2010-07-19 | 2012-02-16 | Alcon Res Ltd | Methods and compositions for the treatment of allergy |
US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
CA2831680C (en) * | 2011-04-21 | 2020-04-21 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
WO2013039785A2 (en) | 2011-09-12 | 2013-03-21 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
LT3461825T (lt) * | 2011-09-30 | 2023-08-25 | C&C Research Laboratories | Nauji heterocikliniai dariniai ir jų panaudojimas |
EP2763677B1 (en) * | 2011-10-04 | 2020-02-26 | Janus Biotherapeutics, Inc. | Novel imidazole quinoline-based immune system modulators |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
WO2014087208A2 (en) * | 2012-12-06 | 2014-06-12 | Enaltec Labs Pvt. Ltd. | A process of preparing alcaftadine |
RU2721418C2 (ru) | 2013-02-01 | 2020-05-19 | Веллстат Терапьютикс Корпорейшн | Соединения амина, имеющие противовоспалительную, противогрибковую, противопаразитарную и противораковую активность |
US20160039842A1 (en) * | 2013-03-15 | 2016-02-11 | Epigenetix, Inc. | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors |
RU2688161C2 (ru) * | 2013-07-25 | 2019-05-20 | Университет Ягеллоньски | Пирролохинолиновые производные в качестве 5-нт6 антагонистов, способ их получения и применение |
EP3307067B1 (en) * | 2015-06-11 | 2022-11-02 | Merck Sharp & Dohme LLC | Aminopyrazine compounds with a2a antagonist properties |
WO2018139876A1 (ko) | 2017-01-26 | 2018-08-02 | 동화약품주식회사 | 신규한 [1, 2, 4] 트리아졸로 [4, 3-a]퀴녹살린 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 bet 단백질 관련 질환의 예방 또는 치료용 약학적 조성물 |
WO2019177971A1 (en) * | 2018-03-12 | 2019-09-19 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
WO2019200500A1 (zh) * | 2018-04-15 | 2019-10-24 | 苏州大学张家港工业技术研究院 | 1,2,4-三氮唑及其制备方法 |
TW202021969A (zh) * | 2018-05-31 | 2020-06-16 | 南韓商C&C新藥研究所 | 雜環衍生物及其用途 |
CN109705141B (zh) * | 2019-02-20 | 2020-05-29 | 苏州大学 | 一种恶唑并喹啉类化合物及其制备方法与应用 |
WO2021098734A1 (zh) * | 2019-11-19 | 2021-05-27 | 南京明德新药研发有限公司 | 作为atm抑制剂的有取代的喹啉吡咯酮类合物及其应用 |
US11530218B2 (en) | 2020-01-20 | 2022-12-20 | Incyte Corporation | Spiro compounds as inhibitors of KRAS |
WO2021231526A1 (en) | 2020-05-13 | 2021-11-18 | Incyte Corporation | Fused pyrimidine compounds as kras inhibitors |
US11767320B2 (en) | 2020-10-02 | 2023-09-26 | Incyte Corporation | Bicyclic dione compounds as inhibitors of KRAS |
EP4067357A1 (en) * | 2021-03-30 | 2022-10-05 | JW Pharmaceutical Corporation | Novel crystalline form of 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-n-methylazetidin-3-amine hydrogen sulfate monohydrate |
WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
WO2024027370A1 (zh) * | 2022-08-03 | 2024-02-08 | 上海和誉生物医药科技有限公司 | 一种含氮三稠环prmt5抑制剂,其制备方法和药学上的用途 |
WO2024067433A1 (zh) * | 2022-09-26 | 2024-04-04 | 上海湃隆生物科技有限公司 | 新型prmt5抑制剂及其应用 |
WO2024069235A2 (en) | 2022-09-30 | 2024-04-04 | Sixfold Bioscience Ltd. | Compositions containing oligonucleotides with theranostic applications |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4053600A (en) * | 1973-03-08 | 1977-10-11 | Sandoz, Inc. | Tricyclic 1,2,4-triazolo-quinazolines |
US4495187A (en) * | 1982-10-18 | 1985-01-22 | Pfizer Inc. | Method of using [1,2,4]triazolo[4,3-a]quinoxaline-4-amine derivatives as antidepressant and antifatigue agents |
IN160956B (es) * | 1982-10-18 | 1987-08-22 | Pfizer | |
BR9814628A (pt) * | 1997-11-11 | 2001-11-27 | Ono Pharmaceutical Co | Derivados de pirazina fundidos |
JP2005523244A (ja) * | 2001-12-21 | 2005-08-04 | ジエイエスダブリユー−リサーチ・フオルシユンクスラバー・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | ピラゾリル置換トリアゾロキノキサリン |
WO2008031556A2 (en) * | 2006-09-12 | 2008-03-20 | Ucb Pharma, S.A. | 2 amino-pyrimidine derivatives as h4 receptor antagonists, processes for preparing them and their use in pharmaceutical compositions |
EP1972629A1 (en) * | 2007-03-23 | 2008-09-24 | Mutabilis SA | New imidazolo-heteroaryl derivatives with antibacterial properties |
FR2921927B1 (fr) * | 2007-10-03 | 2012-10-12 | Univ De Montpellier 1 | Imidazo°1,2-a!quinoxalines et derives pour le traitement des cancers |
-
2009
- 2009-09-10 US US12/556,866 patent/US20100120741A1/en not_active Abandoned
- 2009-09-10 CA CA2735369A patent/CA2735369A1/en not_active Abandoned
- 2009-09-10 RU RU2011113419/04A patent/RU2011113419A/ru not_active Application Discontinuation
- 2009-09-10 JP JP2011526310A patent/JP2012502067A/ja active Pending
- 2009-09-10 TW TW098130500A patent/TW201024297A/zh unknown
- 2009-09-10 CN CN2009801427590A patent/CN102388044A/zh active Pending
- 2009-09-10 EP EP09813607A patent/EP2324029A4/en not_active Withdrawn
- 2009-09-10 UY UY0001032111A patent/UY32111A/es not_active Application Discontinuation
- 2009-09-10 AU AU2009291719A patent/AU2009291719A1/en not_active Abandoned
- 2009-09-10 MX MX2011002264A patent/MX2011002264A/es not_active Application Discontinuation
- 2009-09-10 AR ARP090103487A patent/AR073574A1/es not_active Application Discontinuation
- 2009-09-10 WO PCT/US2009/056519 patent/WO2010030785A2/en active Application Filing
- 2009-09-10 KR KR1020117008096A patent/KR20110095857A/ko not_active Application Discontinuation
-
2011
- 2011-02-28 CL CL2011000431A patent/CL2011000431A1/es unknown
- 2011-11-21 US US13/301,131 patent/US20120065187A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2011002264A (es) | 2011-05-23 |
TW201024297A (en) | 2010-07-01 |
JP2012502067A (ja) | 2012-01-26 |
US20120065187A1 (en) | 2012-03-15 |
RU2011113419A (ru) | 2012-10-20 |
AU2009291719A1 (en) | 2010-03-18 |
EP2324029A4 (en) | 2011-09-14 |
WO2010030785A3 (en) | 2010-07-01 |
US20100120741A1 (en) | 2010-05-13 |
AR073574A1 (es) | 2010-11-17 |
EP2324029A2 (en) | 2011-05-25 |
CN102388044A (zh) | 2012-03-21 |
CL2011000431A1 (es) | 2012-01-20 |
WO2010030785A2 (en) | 2010-03-18 |
CA2735369A1 (en) | 2010-03-18 |
KR20110095857A (ko) | 2011-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32110A (es) | Inhibidores de aminopirimidina de los receptores de histamina para el tratamiento de una enfermedad | |
UY32111A (es) | Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad | |
UY33272A (es) | Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad | |
UY33271A (es) | Inhibidores heterocíclicos de los receptores de histamina para el tratamiento de una enfermedad | |
CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
WO2011112687A3 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
CR11818A (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
CO6430459A2 (es) | Derivados de prolina como inhibidores de catepsina | |
GT201300258A (es) | Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa | |
TR201901886T4 (tr) | DNA-PK inhibitörleri. | |
CR20110560A (es) | Métodos de tratamiento para tumores sólidos | |
PA8841901A1 (es) | Compuestos orgánicos | |
EA201001372A1 (ru) | Формы рифаксимина и их применение | |
PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
CR20110339A (es) | Compuestos útiles para inhibir chk1 | |
CO6460766A2 (es) | Compuestos de haloalquil heteroaril benzamida | |
GT200500360A (es) | Compuestos organicos | |
UY34165A (es) | ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?. | |
DOP2011000009A (es) | Amidofenoxiindazoles utiles como inhibidores de c-met | |
UY33497A (es) | Derivados de espiro-piperidina como moduladores s1p | |
UY32849A (es) | Inhibidores heteroarilicos biciclicos de pde4 | |
CU20140072A7 (es) | Derivados de dihidro-oxazina y dihidro-pirido-oxazina | |
GT201200138A (es) | Derivados de sulfonamida heterocíclicos útiles como inhibidores de mek | |
HN2012000023A (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
BRPI0911577A2 (pt) | derivados espiro-indol para o tratamento de doenças parasíticas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20181114 |